Skip to main content
. 2023 Sep 19;114(12):4664–4676. doi: 10.1111/cas.15966

FIGURE 5.

FIGURE 5

Proposed combination treatment strategy to tackle p53‐mutant esophageal squamous cell carcinoma (ESCC) tumors with a WEE1 inhibitor. Cotreatment with trifluridine (FTD) and MK1775 inhibited ataxia telangiectasia and Rad3‐related protein (ATR)‐checkpoint kinase 1 (CHK1)‐WEE1, a compensation DNA damage response pathway in p53‐mutant ESCC cells, resulting in cytotoxicity via synthetic lethality.